The Division is currently soliciting ideas for Programming for the 2009 EB meetings in New Orleans.  If you have an idea for a symposium or for divisional programming, please CLICK HERE

Chair:  Steven R. Goldberg

	Introduction: Cannabinoid CB1 receptor interdependence with other receptor systems as a target for medication development  Steven R.Goldberg, NIDA, NIH
	Cannabinoid CB1 receptors form functional heteromers with dopamine, adenosine and opioid receptors Sergi Ferre, NIDA, NIH
	Drug-discrimination and in-vivo microdialysis procedures for studying adenosinergic, nicotinic, dopaminergic and opioid receptor interactions with cannabinoid CB1 receptors in rats.  Marcello Solinas, University of Poitiers, France
	Drug self-administration and conditioned place preference procedures for studying interactions between cannabinoid CB1 receptors and other receptor systems in rodents  Walter Fratta, University of Cagliari, Italy
	Intravenous drug self-administration procedures in nonhuman primates for studying interactions between cannabinoid CB1 receptors and other receptor systems  Zuzana Justinova, University of Maryland School of Medicine
	Cannabinoid CB1 receptor interdependence with other receptor systems as a target for medication development: Future directions and potential payoff for human health in the next 10 years   Daniele Piomelli, University of California-Irvine

Translational Research in Behavioral Pharmacology - Division for Behavioral Pharmacology  Chairs:  Charles P. France and Alice M. Young

	Translational medicine in pain research. James E. Barrett, Drexel University College of Medicine
	Challenging the opiates: Concept, target identification and profile of the central analgesic, F 13640.  Francis C. Colpaert, Centre de Recherche Pierre Fabre, Castres, France
	Use of behavioral pharmacology in rational drug discovery for novel targets in psychiatric disorders.  Darryle D. Schoepp, Merck and Co.
	Cognitive disturbances in depression: Preclinical targets for antidepressant treatment.  Alan Frazer, University of Texas Health Science Center at San Antonio

Pharmacotherapeutics for Drug Abuse - The Cocaine Challenge (Division for Behavioral Pharmacology)  Chair:  Alice M. Young

	Pharmacological modification of drug taking: Origins and evolution. William Woolverton, University of Mississippi Medical Center
	Cocaine: Consequences of rapid elimination.  James H. Woods, University of Michigan Medical School
	Benztropine-related dopamine uptake blockers that prevent cocaine effects.  Jonathan Katz, NIDA, NIH
	Employment-based reinforcement in the treatment of cocaine addiction.  Kenneth Silverman, Johns Hopkins University
	Where will it go in ten years? Maxine L. Stitzer, Johns Hopkins Bayview Medical Center

Chairs:  Darrell R. Abernethy and Judith K. Jones

	Introduction. Darrell R. Abernethy, U.S. Pharmacopeia
	Approaches to enhance drug safety in the ambulatory outpatient setting.  Michael Murray, University of North Carolina School of Pharmacy
	Identification and evaluation of drug induced disease.  Judith K. Jones, The Degge Group, Ltd., Arlington, VA
	European experience with active surveillance methods to identify drug safety problems.  Sir Alasdair M. Breckenridge, Medicines and Healthcare Products Regulatory Agency, London, U.K.
	Development of informatics to support post-marketing surveillance in the United States.  Kenneth D. Mandl, Harvard-MIT

Neuroplasticity in Addiction:  Picking up the Pieces (Sponsored by the Divisions for Neuropharmacology, Behavioral Pharmacology, Systems & Integrative Pharmacology)  Chair:  Peter W. Kalivas

	Role of animal models in understanding cellular neuroplasticity George F. Koob, Scripps Research Institute
	Role of nucleus accumbens CREB in addiction and depression: Implications for co-morbidity.  William A. Carlezon, Harvard Medical School/McLean Hospital
	Long-term changes in synaptic efficiency by drugs of abuse.       Antonello Bonci, UCSF
	How molecular plasticity in corticolimbic circuitry translates into novel therapeutics.  Peter W. Kalivas, Medical University of South Carolina
	Neural encoding of negative affect and its relationship to drug seeking Robert A. Wheeler, University of North Carolina

Sponsored by the Divisions for Neuropharmacology, Systems & Integrative Pharmacology, Drug Discovery, Development & Regulatory Affairs, Behavioral Pharmacology, Molecular Pharmacology, Clinical Pharmacology, Translational Medicine & Pharmacogenomics  Chair:  Carol A. Murphy

	Topography in drug discovery: The challenge of allosteric modulators Arthur Christopoulos, Monash University, Australia
	Positive allosteric modulation of GABAB receptors: A novel therapeutic strategy for anxiety and drug dependence.   John F. Cryan, University College Cork, UK
	Allosteric modulation of serotonin transporters: Lessons learned from the development of escitalopram  Connie Sanchez, Lundbeck  Research USA
	Allosteric modulation of GPCRs as a novel therapeutic direction for the treatment of CNS disorders  Colleen Niswender, Vanderbilt University Medical Center

Chair:  Palmer W. Taylor

	The era of chemical characterization of ion channel receptors: The importance of investigating  conformation and state changes.  Jean-Pierre Changeux, Institut Pasteur, Paris
	The acetylcholine binding protein: A model system for nicotinic acetylcholine receptor selectivity.  Titia Sixma, The Netherlands Cancer Institute, Amsterdam
	Roles of nicotinic receptors in nicotine addiction and neuroprotection. Henry A. Lester, Cal Tech
	Dynamics in structure-guided drug design: Structurally defined receptors as templates for freeze-frame, click chemistry synthesis of novel ligands.  Palmer W. Taylor, UCSD

Click to enlarge